Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Sells $126,673.94 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,627 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the transaction, the chief operating officer now owns 26,961 shares in the company, valued at $1,300,059.42. This represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Peter Radovich also recently made the following trade(s):

• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Trading Down 2.0 %

NASDAQ MIRM opened at $51.23 on Friday. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $53.49. The company has a 50-day simple moving average of $44.61 and a 200-day simple moving average of $42.17. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market capitalization of $2.46 billion, a PE ratio of -25.36 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue was up 89.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.57) EPS. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Analyst Ratings Changes

MIRM has been the topic of several recent analyst reports. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Leerink Partners increased their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $57.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MIRM. Marshall Wace LLP lifted its stake in shares of Mirum Pharmaceuticals by 35.9% in the 2nd quarter. Marshall Wace LLP now owns 20,520 shares of the company’s stock worth $702,000 after acquiring an additional 5,420 shares during the period. Creative Planning acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $249,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Mirum Pharmaceuticals by 10.8% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 116,054 shares of the company’s stock valued at $4,526,000 after acquiring an additional 11,284 shares during the period. Values First Advisors Inc. raised its holdings in shares of Mirum Pharmaceuticals by 20.1% during the third quarter. Values First Advisors Inc. now owns 23,725 shares of the company’s stock valued at $925,000 after acquiring an additional 3,971 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after buying an additional 318 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.